Search results for "Bioinformatics"

showing 10 items of 1632 documents

A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury

2016

AbstractIn preclinical stages of drug development, anticipating potential adverse drug effects such as toxicity is an important issue for both saving resources and preventing public health risks. Current in vitro cytotoxicity tests are restricted by their predictive potential and their ability to provide mechanistic information. This study aimed to develop a metabolomic mass spectrometry-based approach for the detection and classification of drug-induced hepatotoxicity. To this end, the metabolite profiles of human derived hepatic cells (i.e., HepG2) exposed to different well-known hepatotoxic compounds acting through different mechanisms (i.e., oxidative stress, steatosis, phospholipidosis…

Bioquímica0301 basic medicineDrugmedia_common.quotation_subjectMetaboliteBiologyPharmacologymedicine.disease_causeBioinformaticsModels BiologicalArticleMass Spectrometry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMetabolomicsmedicineHumansMetabolomicsToxicologiaPhospholipidsmedia_commonPhospholipidosisMultidisciplinaryHep G2 Cellsmedicine.diseaseGlutathioneFatty LiverOxidative Stress030104 developmental biologychemistryDrug development030220 oncology & carcinogenesisToxicityChemical and Drug Induced Liver InjurySteatosisOxidative stressScientific Reports
researchProduct

Triphen­yl[(4-phenyl­benzo­yl)meth­yl]phospho­nium trifluoro­methane­sulfonate

2010

In the cation of the title compound, C32H26OP+·CF3O3S−, the dihedral angle between the benzene rings of the biphenyl group is 42.37 (8)°. In the crystal, the cations and anions interact through intermolecular C—H...O hydrogen bonds, forming chains parallel to the b axis. These chains are further linked by C—H...π stacking interactions into layers parallel to the bc plane.

BiphenylCrystallographyHydrogen bondStackingMethane sulfonateGeneral ChemistryMeth-Dihedral angleCondensed Matter PhysicsBioinformaticsMedicinal chemistryOrganic PapersCrystalchemistry.chemical_compoundchemistryQD901-999General Materials ScienceBenzeneActa Crystallographica Section E: Structure Reports Online
researchProduct

Functional Genomics of 5-to 8-Cell Stage Human Embryos by Blastomere Single-Cell cDNA Analysis

2010

Blastomere fate and embryonic genome activation (EGA) during human embryonic development are unsolved areas of high scientific and clinical interest. Forty-nine blastomeres from 5- to 8-cell human embryos have been investigated following an efficient single-cell cDNA amplification protocol to provide a template for high-density microarray analysis. The previously described markers, characteristic of Inner Cell Mass (ICM) (n = 120), stemness (n = 190) and Trophectoderm (TE) (n = 45), were analyzed, and a housekeeping pattern of 46 genes was established. All the human blastomeres from the 5- to 8-cell stage embryo displayed a common gene expression pattern corresponding to ICM markers (e.g., …

BlastomeresDNA ComplementaryScienceCell Biology/Developmental Molecular MechanismsBiologyDevelopmental Biology/Molecular DevelopmentmedicineHumansInner cell massHuman embryogenesisBlastocystCell Biology/Gene ExpressionOligonucleotide Array Sequence AnalysisDevelopmental Biology/EmbryologyMultidisciplinaryMicroarray analysis techniquesGene Expression ProfilingGenetics and Genomics/Functional GenomicsQRGenetics and Genomics/Gene ExpressionEmbryoGenomicsBlastomereGenetics and Genomics/BioinformaticsMolecular biologyEmbryonic stem cellDevelopmental Biology/Stem CellsGene expression profilingmedicine.anatomical_structureembryonic structuresMedicineResearch Article
researchProduct

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

2018

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially pr…

Blood GlucoseCardiometabolic parameterGlucagon-Like PeptidesIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticsIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEndothelial dysfunctionMolecular BiologyGlucagon-like peptide 1 receptorLiraglutidebusiness.industryType 2 Diabetes MellitusLiraglutideCardiovascular riskmedicine.diseasePlaque AtheroscleroticType 2 diabetes mellituBlood pressureDiabetes Mellitus Type 2Cardiovascular DiseasesMetabolic control analysisGlucagon-like peptide 1 receptor agonistMolecular Medicinebusinessmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

2018

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might …

Blood GlucoseEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesDiseaseReview Article030204 cardiovascular system & hematologyBioinformaticslcsh:Diseases of the endocrine glands. Clinical endocrinologyIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineHumansHypoglycemic AgentsCause of deathSistema cardiovascularlcsh:RC648-665DiabetisLiraglutidebusiness.industrySemaglutidemedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesHeart failureMalaltiesbusinessmedicine.drugJournal of Diabetes Research
researchProduct

Requirements for claims of favorable effects on serum lipids by oral antidiabetic agents.

1998

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBlood lipidsHyperlipidemiasBioinformaticsDiabetes ComplicationsOral administrationInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansHypoglycemic AgentsAntidiabetic agentsChemotherapybusiness.industryDrugs Investigationalmedicine.diseaseLipidsEndocrinologyCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

The mechanisms of thrombotic risk induced by hormone replacement therapy.

2001

Abstract Objective : To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions : Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemosta…

Blood PlateletsMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentCoronary DiseaseDiseaseBioinformaticsFibrinogenGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundRisk FactorsInternal medicineFibrinolysismedicineHumansHormone replacement therapyEndothelial dysfunctionAgedVenous ThrombosisHemostasisFactor VIIbusiness.industryAntithrombinEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle Agedmedicine.diseasePostmenopauseEndocrinologyPhenotypechemistryHemostasisFemaleEndothelium Vascularbusinessmedicine.drugMaturitas
researchProduct

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.

2021

Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and i…

Blood PlateletsQH301-705.5platelet functionMPNInflammationReviewDiseaseBioinformaticsFibrinogenModels BiologicalCatalysisPAR receptorLeukemia Myeloid Chronic Atypical BCR-ABL NegativeInorganic ChemistryTissue factorThrombinAntithromboticmedicineAnimalsHumansThrombophiliaPlateletPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyPAR receptorsbusiness.industryOrganic ChemistryThrombinGeneral MedicineComputer Science ApplicationsChemistryReceptors FibrinogenCoagulationthrombin generationBiological Assayfibrinogenmedicine.symptombusinessmedicine.drugInternational journal of molecular sciences
researchProduct

Influence of metabolic syndrome on hypertension-related target organ damage

2005

Body surface areamedicine.medical_specialtyKidneybusiness.industryEnd organ damageLeft ventricular hypertrophymedicine.diseaseBioinformaticsEssential hypertensionEndocrinologymedicine.anatomical_structureHypertensive retinopathyDiabetes mellitusInternal medicineInternal MedicinemedicineMetabolic syndromebusinessAmerican Journal of Hypertension
researchProduct